Attached files
| file | filename |
|---|---|
| EX-99.2 - EXHIBIT 99.2 - IMMUNE DESIGN CORP. | exhibit992asco.htm |
| EX-99.1 - EXHIBIT 99.1 - IMMUNE DESIGN CORP. | exhibit991earnings1q17.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 17, 2017
IMMUNE DESIGN CORP.
(Exact name of registrant as specified in its charter)
Delaware | 001-36561 | 26-2007174 |
(state or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
1616 Eastlake Ave. E., Suite 310 Seattle, Washington | 98102 | |
(Address of principal executive offices) | (Zip Code) | |
Registrant's telephone number, including area code: (206) 682-0645
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company x | ||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. | Results of Operations and Financial Condition. |
On May 17, 2017, Immune Design Corp. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2017. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information provided in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 8.01. | Other Events. |
On May 17, 2017, the Company also issued a press release reporting new clinical and biomarker data from the Company’s CMB305 and G100 monotherapy studies, which data will be presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO) in June.
A copy of the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
Exhibit Number | Description | |
99.1 | Press Release, dated May 17, 2017. | |
99.2 | Press Release, dated May 17, 2017. | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IMMUNE DESIGN CORP. | |
By: | /s/ Carlos Paya, M.D., Ph.D. |
Carlos Paya, M.D., Ph.D. | |
President and Chief Executive Officer | |
Dated: May 17, 2017
EXHIBIT INDEX
Exhibit Number | Description | |
99.1 | Press Release, dated May 17, 2017. | |
99.2 | Press Release, dated May 17, 2017. | |